DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, ...
Let’s dig into the relative performance of DexCom (NASDAQ:DXCM) and its peers as we unravel the now-completed Q4 patient ...
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...
Barchart on MSN
DexCom’s quarterly earnings preview: What you need to know
San Diego, California-based DexCom, Inc. (DXCM) is a medical technology company focused on continuous glucose monitoring (CGM ...
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
If you have diabetes, a continuous glucose monitor (CGM) can make testing your blood sugar easier. Instead of pricking your skin multiple times per day, you continuously wear a sensor that sends ...
VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results